Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma

C. W. Hong, S. K. Libutti, B. J. Wood

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Radiofrequency ablation (RFA) is a standard treatment for small, unresectable hepatocellular carcinomas (HCCS). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.

Original languageEnglish (US)
Pages (from-to)274-277
Number of pages4
JournalCurrent Oncology
Volume20
Issue number3
DOIs
StatePublished - Jun 13 2013

    Fingerprint

Keywords

  • Ablation
  • Doxorubicin
  • Hepatocellular carcinoma
  • Liposomes
  • RFA

ASJC Scopus subject areas

  • Oncology

Cite this